Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis

Abstract

Background and Aim

This systematic review and meta‐analysis aimed to compare the effectiveness and safety of molnupiravir and sotrovimab in the treatment of patients with coronavirus disease 2019 (COVID‐19).

Methods

Cochrane Library, Web of Science, PubMed, medRxiv, and Google Scholar were systematically searched to identify relevant evidence up to December 2023. The risk of bias was assessed using the risk of bias in nonrandomized studies of interventions tool. Data were analyzed using Comprehensive Meta‐Analysis (CMA).

Results

Our search identified and included 13 studies involving 16166 patients. The meta‐analysis revealed a significant difference between the molnupiravir and sotrovimab groups in terms of the mortality rate (odds ratio [OR] = 2.07, 95% confidence interval [CI]: 1.16, 3.70). However, no significant difference was observed between the two groups in terms of hospitalization rate (OR = 0.71, 95% CI: 0.47, 1.06), death or hospitalization rate (OR = 1.51, 95% CI: 0.81, 2.83), and intensive care unit admission (OR = 0.59, 95% CI: 0.07, 4.84). In terms of safety, molnupiravir was associated with a higher incidence of adverse events (OR = 1.67, 95% CI: 1.21, 2.30).

Conclusion

The current findings indicate that sotrovimab may be more effective than molnupiravir in reducing the mortality rate in COVID‐19 patients. However, no statistical difference was observed between the two treatments for other effectiveness outcomes. The certainty of evidence for these findings was rated as low or moderate. Further research is required to provide a better comparison of these interventions in treating COVID‐19 patients.

Abstract

The present findings may suggest that treatment with sotrovimab is more effective than molnupiravir in reducing mortality rate in COVID‐19 patients. No significant difference was observed between the molnupiravir and sotrovimab in terms of hospitalization rate, death or hospitalization rate, and intensive care unit (ICU) admission. Molnupiravir was associated with higher incidence of adverse events.